More about

Nivolumab

News
April 27, 2022
3 min read
Save

Immunotherapy before head and neck cancer surgery does not increase complications

Immunotherapy before head and neck cancer surgery does not increase complications

DALLAS — Neoadjuvant immunotherapy did not increase risk for complications among patients who underwent surgery for head and neck cancers, according to study results presented at American Head & Neck Society Annual Meeting.

News
April 23, 2022
5 min read
Save

Esophageal Cancer Awareness Month: Updated guidance, treatment options, FDA news and more

Esophageal Cancer Awareness Month: Updated guidance, treatment options, FDA news and more

Esophageal cancer is one of the deadliest forms of cancer with an estimated 19,260 diagnoses and 15,530 deaths in the United States last year, the American Association for Cancer Research reported.

News
April 12, 2022
4 min read
Save

Neoadjuvant nivolumab plus chemotherapy extends EFS in non-small cell lung cancer

Neoadjuvant nivolumab plus chemotherapy extends EFS in non-small cell lung cancer

Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting.

News
April 06, 2022
1 min watch
Save

VIDEO: Ongoing trial on use of radiotherapy with ipilimumab, nivolumab in metastatic RCC

VIDEO: Ongoing trial on use of radiotherapy with ipilimumab, nivolumab in metastatic RCC

Mark W. Ball, MD, spoke with Healio about an ongoing phase 2 study assessing the use of cytoreductive stereotactic hypofractionated radiotherapy along with ipilimumab and nivolumab in patients with metastatic renal cell carcinoma.

News
March 21, 2022
1 min read
Save

FDA approves Opdualag for unresectable or metastatic melanoma

FDA approves Opdualag for unresectable or metastatic melanoma

The FDA approved relatlimab plus nivolumab for treatment of patients aged 12 years or older with unresectable or metastatic melanoma.

News
March 18, 2022
3 min read
Save

Relatlimab plus nivolumab shows ‘consistent PFS benefit’ in advanced melanoma

Relatlimab plus nivolumab shows ‘consistent PFS benefit’ in advanced melanoma

Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with previously untreated metastatic or unresectable melanoma, according to a study presented during an ASCO Plenary Series session.

News
March 18, 2022
2 min read
Save

Perioperative Opdivo alone, in combination with Yervoy safe in patients with HCC

Perioperative Opdivo alone, in combination with Yervoy safe in patients with HCC

Nivolumab alone or in combination with ipilimumab was safe and well-tolerated in patients with resectable hepatocellular carcinoma in the perioperative setting, according to a study published in Lancet Gastroenterology and Hepatology.

News
March 14, 2022
1 min read
Save

Phase 3 trial of combination for advanced melanoma misses primary endpoints

A phase 3 trial designed to assess the addition of bempegaldesleukin to nivolumab for previously untreated unresectable or metastatic melanoma failed to meet its primary endpoint, according to the agents’ manufacturers.

News
March 07, 2022
1 min read
Save

FDA approves neoadjuvant Opdivo regimen for non-small cell lung cancer

FDA approves neoadjuvant Opdivo regimen for non-small cell lung cancer

The FDA approved nivolumab with platinum doublet chemotherapy as neoadjuvant treatment for adults with resectable non-small cell lung cancer.

News
February 28, 2022
1 min read
Save

FDA grants priority review to Opdivo for non-small cell lung cancer indication

FDA grants priority review to Opdivo for non-small cell lung cancer indication

The FDA granted priority review to nivolumab for use with chemotherapy as neoadjuvant treatment of patients with resectable non-small cell lung cancer.

View more